Ex Vivo-expanded Allogeneic Gamma 9 Delta 2 T-cells
ex vivo-expanded allogeneic gamma 9 delta 2 t-cells
"A preparation of a subset of ex vivo-expanded, allogeneic T-lymphocytes that express gamma 9 delta 2 T-cell receptors (TCRs), with potential immunomodulating and antineoplastic activities. Upon administration of the ex vivo-expanded allogeneic gamma 9 delta 2 T-cells, these cells secrete interferon-gamma (IFN-g) and exert direct killing of tumor cells. In addition, these cells activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against tumor cells. Gamma delta T-lymphocytes play a key role in the activation of the immune system and do not require major histocompatibility complex (MHC)-mediated antigen presentation to exert their cytotoxic effect. Gamma 9 delta 2 T-cells, a subset of gamma delta T-cells, may have a stronger association with antitumor immune responses compared with other gamma delta T-cell subtypes."